Brief: Onxeo Enters Into Agreements With Acrotech Biopharma LLC

Valerio Therapeutics SA

06/04/2020 17:35

April 6 (Reuters) - ONXEO SA  C4X.PA :
    * ONXEO TO RECEIVE $6.6 MILLION BY GRANTING ADDITIONAL
EXCLUSIVE
RIGHTS TO BELINOSTAT TO ACROTECH BIOPHARMA LLC
    * THIS TRANSACTION COMPLETES ONXEO’S STRATEGIC TRANSITION TO
A
COMPANY SOLELY FOCUSED ON DNA DAMAGE RESPONSE (DDR) ACTIVITIES
IN ONCOLOGY
    * $6.6M RECEIVED FROM ACROTECH EXTENDS ONXEO'S CASH RUNWAY
INTO Q2
2021 AND SUPPORTS COMPANY'S DDR-RELATED PROGRAMS
    * ONXEO WILL RECORD IMPAIRMENT CHARGE OF ABOUT EUR 13
MILLION IN
ITS 2019 CONSOLIDATED ACCOUNTS

Source text for Eikon:  ID:nBw8pB94sa 
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))